Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 21, 2004. The report primarily discloses changes in directors' interests in the company's Ordinary Shares rather than providing comprehensive financial results.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Share Price: GBP 12.07 per share.
- Transaction Volume: 1,181 shares purchased for the SmithKline Beecham Bonus Investment Plan and 7,609 shares for the GlaxoSmithKline Annual Investment Plan.
Material Changes
The filing details purchases of Ordinary Shares by the SmithKline Beecham Employee Benefit Trust ("the Trust") on October 20, 2004. These purchases were made for participants in employee investment plans. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine disclosure regarding director interests.
Important Facts for Investors
- Director John Coombe holds an interest in shares held by the SmithKline Beecham Employee Benefit Trust, consistent with other non-US employees.
- The Trust is a discretionary fund for non-US employees and former employees of GlaxoSmithKline plc and its subsidiaries.
- This report does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial statements.